PDCD1 and neoplasm: PD-L1 is highly inducible and expressed on many cancers in response to anti-tumor immune activity and inhibits PD-1+ tumor antigen-specific CD8+ T cells (87), representing a key mechanism underlying cancer adaptive immune resistance.